

## PRODUCT RELEASE

**Collectis bioresearch launches Compact TALEN™  
the next generation of TAL effector nucleases**

**Paris (France), September 23, 2013 - [Collectis bioresearch](#), a subsidiary of Collectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of a monomeric [Compact TALEN™](#), that allows efficient transfection and genome editing in sensitive cells.**

Transfection of sensitive cells such as primary cells, plant cells and iPS cells is the major limitation for efficient genome editing. To breakdown this barrier, Collectis scientists have developed a monomeric TALEN™, distributed under the name Compact TALEN™. In contrast to Custom TALEN™, the monomeric Compact TALEN™ requires the expression of only one DNA or RNA molecule to be active. This exquisite property, not only ease DNA/RNA cell transfection but offers a tremendous advantage to scientist who have to use viral shuttles for vectorization. The Collectis Group is the first in its sector to develop and market such a tool. This technology greatly simplifies the design and synthesis as well as the therapeutic delivery of nucleases.

This new product based on Collectis' proprietary TAL effector nuclease technology makes it possible to target specific DNA segments using just a single molecule, as shown in the innovative study on ultra-precise Compact TALEN™ published in the scientific journal Nature Communications:

[Nat Commun](#). 2013;4:1762. doi: 10.1038/ncomms2782.

**Compact designer TALENs for efficient genome engineering.**

[Beurdeley M](#), [Bietz F](#), [Li J](#), [Thomas S](#), [Stoddard T](#), [Juillerat A](#), [Zhang F](#), [Voytas DF](#), [Duchateau P](#), [Silva GH](#).

Collectis, Research and Development

Compact TALEN™ constitutes a breakthrough in the fields of genome engineering and synthetic biology. This technology is covered by an international patent application published under WO 2012/138927.

**For further information please visit our website [www.collectis-bioresearch.com](http://www.collectis-bioresearch.com)  
or [contact@collectis-bioresearch.com](mailto:contact@collectis-bioresearch.com)**

**About Collectis bioresearch**

Established in 2008 as a subsidiary of Collectis, Collectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning Custom TALEN™ Services. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.

**About Collectis**

Founded in France in 1999, the Collectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bioenergies. Collectis was cofounded by André Choulika, its Chairman and CEO, and is now one of the world's top companies in the field of genome engineering, with revenue of \$27 million in 2012. Leading the field of pluripotent stem cells, Collectis has developed expertise in drug discovery, toxicity testing, and

regenerative medicine. Cellectis has a solid background in the large-scale handling of stem cells up until their maturation and differentiation into functional cell types. We employ a workforce of 230 people at 5 sites worldwide: New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States, Gothenburg in Sweden, and Paris & Evry in France.

The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. Our clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.

For more information, visit our website: [www.cellectis.com](http://www.cellectis.com).

**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

**For further information, please contact:**

**Cellectis**

Philippe Valachs

Company Secretary

Tel: +33 (0)1 81 69 16 00

[media@cellectis.com](mailto:media@cellectis.com)